Top Abstract Purchase Related
Home
>
Node
>
Subnode

Structure-activity relationships and pharmacological profiles of new 5-HT (1) receptor agonists as antimigraine agents

Perez, M.; John, G.W.

Current Opinion in Drug Discovery and Development 2(4): 304-310

1999

ISSN/ISBN: 1367-6733
PMID: 19649958
Document Number: 502362
The design of new generation drugs acting as 5-HT1 receptor agonists, in the field of acute treatment of migraine, is still very active. The reason is the need for safer medicines with improved response rates and a reduced rate of headache recurrence. This review focuses on the different classes of drugs, which have been classified based on the target upon which they act rather than upon structural characteristics. Short SAR studies are reported for each series with a detailed pharmacological profile for the most interesting compounds.

Document emailed within 1 workday
Secure & encrypted payments

Ebert, B.; Madsen, U.; Johansen, T.N.; Krogsgaard-Larsen, P. 1991: NMDA receptor agonists: relationships between structure and biological activity Advances in Experimental Medicine and Biology 287: 483-487
Labrid, C.; Regnier, G.; Laubie, M. 1983: Almitrine bismesylate: pharmacological review and structure-activity relationships European Journal of Respiratory Diseases. Supplement 126: 185-189
Rey, A. 1974: Cholinergic and anticholinergic agents. Structure-activity relationships. II. Benzilates Il Farmaco; Edizione Scientifica 29(4): 281-293
Mager, P.P. 1975: MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA Arzneimittel-Forschung 25(11): 1745
Mager, P.P. 1975: MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA Arzneimittel-Forschung 25(9): 1355-1356
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z. 1980: Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
Atherton, F.R.; Hall, M.J.; Hassall, C.H.; Lambert, R.W.; Ringrose, P.S. 1979: Phosphonopeptides as antibacterial agents: rationale, chemistry, and structure-activity relationships Antimicrobial Agents and Chemotherapy 15(5): 677-683
Debaert, M. 2001: Developments in anti-malaria agents: chemical data, structure-activity relationships Annales Pharmaceutiques Francaises 59(2): 75-84
Kojima, E.; Shirasaka, T.; Machida, M.; Yoshioka, H.; Murakami, K.; Mitsuya, H. 1991: Synthesis and structure-activity relationships of 2',3'-dideoxypurine nucleosides as potential antiretroviral agents Nucleic Acids Symposium Series 25: 91-92
Kim, R.S.; LaBella, F.S.; Zunza, H.; Zunza, F.; Templeton, J.F. 1980: Progesterone derivatives that bind to the digitalis receptor: structure--activity relationships Molecular Pharmacology 18(3): 402-405
Fossa, P.; Boggia, R.; Lo Presti, E.; Mosti, L.; Dorigo, P.; Floreani, M. 1997: Inotropic Agents. Synthesis and Structure-Activity Relationships of new Milrinone Related Camp Pde Iii Inhibitors Farmaco 52(8-9): 523-530
Mailliet, P.; Segal-Bendirdjian, E.; Kozelka, J.; Barreau, M.; Baudoin, B.; Bissery, M.C.; Gontier, S.; Laoui, A.; Lavelle, F.; Le Pecq, J.B. 1995: Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships Anti-Cancer Drug Design 10(1): 51-73
Carbone, V.; Kim, H.; Huang, J.X.; Baker, M.A.; Ong, C.; Cooper, M.A.; Li, J.; Rockman, S.; Velkov, T. 2013: Molecular characterization of the receptor binding structure-activity relationships of influenza B virus hemagglutinin Acta Virologica 57(3): 313-332
Ferguson, L.R.; Baguley, B.C. 1981: Induction of petite formation in Saccharomyces cerevisiae by experimental antitumour agents. Structure--activity relationships for 9-anilinoacridines Mutation Research 90(4): 411-423
Krause, M.; Rouleau, A.; Stark, H.; Garbarg, M.; Schwartz, J.C.; Schunack, W. 1996: Structure-activity relationships of novel azomethine prodrugs of the histamine H3-receptor agonist (R)-alpha-methylhistamine: from alkylaryl to substituted diaryl derivatives Die Pharmazie 51(10): 720-726
Fernández, B.; Kaumann, A.J. 1975: Structure-basicity and structure-affinity relationships of beta-adrenergic blocking agents Acta Physiologica Latino Americana 25(1): 45-51
Mager, H.; Barth, A. 1979: Problems involved in the specification and interpretation of quantitative structure-activity relationships. Part 1: a modified type of structure-activity equations Die Pharmazie 34(9): 557-559
Matsuda, T.; Ago, Y.; Takuma, K. 2012: Pharmacological profiles of galantamine: the involvement of muscarinic receptor Nihon Shinkei Seishin Yakurigaku Zasshi 32(1): 1-8
Handley, D.A.; Van Valen, R.G.; Winslow, C.M.; Tomesch, J.C.; Saunders, R.N. 1987: In vitro and in vivo pharmacological profiles of the PAF receptor antagonist SRi 63-675 Thrombosis and Haemostasis 57(2): 187-190
Seiler, S.M.; Peluso, M.; Tuttle, J.G.; Pryor, K.; Klimas, C.; Matsueda, G.R.; Bernatowicz, M.S. 1996: Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists Molecular Pharmacology 49(1): 190-197